Philip A. van Damme
Fondateur chez Stichting Sanammad
Profil
Philip A.
van Damme is the founder who has founded Stichting Sanammad in 2009 and Sanammad Pharmaceuticals BV in 2014, where he holds the title of President & Director.
He was also a former Director, Chief Scientific & Medical Officer at AXIM Biotechnologies, Inc. from 2014 to 2020 and a former Director at CanChew Biotechnologies LLC from 2012 to 2013.
Dr. van Damme earned a doctorate degree from the University of Utrecht in 1983.
Postes actifs de Philip A. van Damme
Sociétés | Poste | Début |
---|---|---|
Stichting Sanammad | Fondateur | 01/01/2009 |
Sanammad Pharmaceuticals BV | Fondateur | 01/01/2014 |
Anciens postes connus de Philip A. van Damme
Sociétés | Poste | Fin |
---|---|---|
AXIM BIOTECHNOLOGIES, INC. | Directeur Technique/Scientifique/R&D | 06/05/2020 |
CanChew Biotechnologies LLC
CanChew Biotechnologies LLC Pharmaceuticals: OtherHealth Technology CanChew Biotech focuses on the treatment of pain and other medical disorders with the application of chewing gum based cannabis/cannabinoids medical products. The company targets on the R&D and execution of their clinical development plan and subsequently out licensing of their technology. The development focuses on the R&D of the formulation, production and the development of chewing gum based products in their respective fields e.g.: for the treatment of numerous diseases like pain, nausea and vomiting, anorexia, spasticity and various other symptoms. | Directeur Technique/Scientifique/R&D | - |
Formation de Philip A. van Damme
University of Utrecht | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
AXIM BIOTECHNOLOGIES, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
CanChew Biotechnologies LLC
CanChew Biotechnologies LLC Pharmaceuticals: OtherHealth Technology CanChew Biotech focuses on the treatment of pain and other medical disorders with the application of chewing gum based cannabis/cannabinoids medical products. The company targets on the R&D and execution of their clinical development plan and subsequently out licensing of their technology. The development focuses on the R&D of the formulation, production and the development of chewing gum based products in their respective fields e.g.: for the treatment of numerous diseases like pain, nausea and vomiting, anorexia, spasticity and various other symptoms. | Health Technology |
Stichting Sanammad | Miscellaneous |
Sanammad Pharmaceuticals BV |